1. Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: a PRISMA‐compliant systematic review—An EAACI position paper
- Author
-
M. Gotua, Pascal Demoly, Marina Atanaskovic-Markovic, Knut Brockow, Munir Pirmohamed, Antonino Romano, Josefina Cernadas, Vincent Yip, Cristobalina Mayorga, Andreas J. Bircher, Abderrahim Oussalah, Jean-Christoph Roger J-P Caubet, Ingrid Terreehorst, Annick Barbaud, Jose Julio Laguna, Jean-Louis Guéant, Luciana Kase-Tanno, Miguel Blanca, Alla Nakonechna, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Biochimie – Biologie moléculaire et Nutrition [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), University of Liverpool, Royal Liverpool and Broadgreen University Hospital NHS Trust, Institute of Translational Medicine, University of Liverpool, Instituto de Investigación Biomédica [Malaga, Spain] (IBIMA), Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga [Spain], Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hospital de São João [Porto], Hospital Lusíadas Porto, Tbilisi State University, Technische Universität München [München] (TUM), Geneva University Hospitals and Geneva University, University Hospital Basel [Basel], University of Belgrade [Belgrade], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hospital Sírio-Libanês [São Paulo, Brazil], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Hospital Central de la Cruz Roja San Jose y Santa Adela, Clinica G.B. Morgagni (Fondazione Mediterranea), Ear, Nose and Throat, AII - Inflammatory diseases, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Salvy-Córdoba, Nathalie, Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Allergy Unit [Cruz Roja-Madrid], Faculté de Médecine [Nancy], Université de Lorraine (UL), Royal Liverpool University Hospital, and University of Liverpool-Royal Liverpool and Broadgreen University Hospital NHS Trust
- Subjects
0301 basic medicine ,MESH: Carbamazepine ,MESH: Drug Hypersensitivity ,Genetic variants ,T-Lymphocytes ,Dapsone ,0302 clinical medicine ,systematic review ,Abacavir ,human leukocyte antigen genes ,Immunology and Allergy ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,media_common ,ddc:618 ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,3. Good health ,[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences ,Carbamazepine ,Pharmaceutical Preparations ,Drug Hypersensitivity Syndrome ,T cell-mediated drug hypersensitivity reactions ,T cell–mediated drug hypersensitivity reactions ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,medicine.drug ,Drug ,Nevirapine ,media_common.quotation_subject ,MESH: Pharmaceutical Preparations ,Immunology ,Human leukocyte antigen ,Drug Hypersensitivity ,03 medical and health sciences ,MESH: Drug Hypersensitivity Syndrome ,medicine ,Humans ,cutaneous adverse drug reactions ,MESH: Humans ,business.industry ,genetic variants ,Cutaneous adverse drug reactions ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,medicine.disease ,Toxic epidermal necrolysis ,030104 developmental biology ,Human leukocyte antigen genes ,MESH: T-Lymphocytes ,030228 respiratory system ,HLA-B Antigens ,Stevens-Johnson Syndrome ,Systematic review ,MESH: HLA-B Antigens ,MESH: Stevens-Johnson Syndrome ,business ,Pharmacogenetics ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell-mediated reactions classically occur more than 6 hours after drug administration and include life-threatening conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA-B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA-compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123 548 controls) have been included in the review reporting genetic associations with carbamazepine (n = 31), other aromatic antiepileptic drugs (n = 24), abacavir (n = 11), nevirapine (n = 14), trimethoprim-sulfamethoxazole (n = 11), dapsone (n = 4), allopurinol (n = 10), and other drugs (n = 5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future.
- Published
- 2020
- Full Text
- View/download PDF